RESUMEN
The electropolymerized molecularly imprinted polymers (MIP) have enabled the utilization of various functional monomers with superior selective recognition of the target analyte template. Methyldopa is an attractive synthetic dopamine analogue which has phenolic, carboxylic, and aminic functional groups. In this research, methyldopa was exploited to fabricate selective MIPs, for the detection of sofosbuvir (SFB), by a simple electropolymerization step onto a disposable pencil graphite electrode (PGE) substrate. The interaction between methyldopa, as a functional monomer, and a template has been investigated experimentally by UV spectroscopy. A polymethyldopa (PMD) polymer was electrografted onto PGE in the presence of SFB as a template. X-ray photoelectron spectroscopy (XPS), electrochemical impedance spectroscopy (ESI), and cyclic voltammetry (CV) were used for the characterization of the fabricated sensor. Differential pulse voltammetry (DPV) of a ferrocyanide/ferricyanide redox probe was employed to indirectly detect the SFB binding to the MIP cavities. The sensor shows a reproducible and linear response over a dynamic linear range from 1.0 × 10-11 M to 1.0 × 10-13 M of SFB with a limit of detection of 3.1 × 10-14 M. The sensor showed high selectivity for the target drug over structurally similar and co-administered interfering drugs, and this enabled its application to detect SFB in its pharmaceutical dosage form and in spiked human plasma samples.
RESUMEN
Pathogenic microorganisms are responsible for many diseases in biological organisms, including humans. Many of these infections thrive in hospitals, where people are treated with medicines and certain bacteria resist those treatments. Consequently, this research article aims to develop efficient antimicrobial material-based conjugated and functionalized polypropargyl alcohol nanoparticles (nano-PGA) synthesized by gamma irradiation. The monomer of PGA was polymerized in various mediums (water (W), chloroform (Ch), and dimethylformamide (DMF)) without catalysts under the action of γ-rays, producing π-conjugated and colored functional nano-PGA polymers. Nano-PGA is a versatile polymer demonstrated here as suitable for creating next-generation of antimicrobial systems capable of effectively preventing and killing various pathogenic microorganisms. The novelty here is the development of polymeric nanostructures by changing the solvent and irradiation doses. The antimicrobial property of nano-PGA (nanostare-like antibody structure) was examined against different pathogenic bacteria and unicellular fungi. Nano-PGA-DMF exhibits significant antimicrobial potential against Staphylococcus aureus (S. aureus) (20.20 mm; zone of inhibition (ZOI), and 0.47 µg/mL; minimum inhibitory concentration (MIC), followed by Escherichia coli (E. coli) (14.50 mm; ZOI, and 1.87 µg/mL; MIC, and Candida albicans (C.albicans) (12.50 mm; ZOI, and 1.87 µg/mL; MIC). In antibiofilm results, the highest inhibition percentage of the synthesized nano-PGA-W, nano-PGA-Ch, and nano-PGA-DMF was documented for S. aureus (17.01%, 37.57%, and 80.27%), followed by E. coli (25.68%, 55.16% and 78.11%), and C.albicans (40.10%, 62.65%, and 76.19%), respectively. The amount of bacterial protein removed is directly proportional after increasing the concentration of nano-PGA-W, nano-PGA-Ch, and nano-PGA-DMF samples (at different concentrations) and counted to be 70.58, 102.89, and 200.87 µg/mL, respectively following the treatment with 1.0 mg/mL of each sample. It was found that the nano-PGA polymer prepared in DMF has better antimicrobial activity than one prepared in chloroform than in water.
Asunto(s)
Antiinfecciosos , Staphylococcus aureus , Antibacterianos/química , Antibacterianos/farmacología , Antiinfecciosos/química , Antiinfecciosos/farmacología , Bacterias , Proteínas Bacterianas , Candida albicans , Escherichia coli , Pruebas de Sensibilidad Microbiana , Polímeros , Farmacorresistencia Bacteriana MúltipleRESUMEN
Insulin growth factor-1 (IGF-1) and growth hormone (GH) have cardiac protective effects through many mechanisms; they can directly oppose endothelial dysfunction in a number of ways. Many studies assessed the effect of GH or IGF-like growth factor 1 in patients with cardiac dysfunction, but no previous study assessed the GH and insulin-like growth factor-1 in renal transplant recipients with and without cardiac dysfunction, especially elderly. Eighty patients with renal transplantation and age limit above 75 years. They were subdivided into two groups according to the presence or absence of cardiac dysfunction based on medical history, clinical findings, electrocardiogram, and echocardiography. Serum GH and insulin-like growth factor-1 were studied by immunoradiometric assay. The echocardiography study was performed. M-mode two-dimensional and Doppler measurements were taken to obtain the four- and five-chamber views, chambers' dimensions, left ventricular end-diastolic dimensions, left ventricular end-systolic dimensions, septal wall thickness (SWT), distance between leading edges of the endocardial and pericardial echoes of left ventricular posterior wall (posterior wall thickness), aortic root and left atrial dimensions (LAD), fractional shortening and ejection fraction. IGF-1 is lower in patients with cardiac dysfunction with renal transplantation with mean value of 61 ± 30.05 than those control group with mean value 145.52 ± 70.5. Level of human growth factor is higher in patients with dysfunction with renal transplantation with mean value 2.62 ± 3.05 than those control group after renal transplantation with mean value 0.85 ± 0.9. No correlations were found between IGF-1 and various echocardiographic parameters. Only SWT and LAD were negatively correlated with GH, r = -0.08, P <0.02, r = -0.37, P <0.03, respectively. No correlation was found between IGF-1 and various echocardiographic parameters. Only SWT and LAD were negatively correlated with GH.
Asunto(s)
Cardiopatías , Hormona de Crecimiento Humana/sangre , Factor I del Crecimiento Similar a la Insulina/análisis , Trasplante de Riñón , Receptores de Trasplantes/estadística & datos numéricos , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Ecocardiografía , Femenino , Atrios Cardíacos/diagnóstico por imagen , Cardiopatías/sangre , Cardiopatías/diagnóstico por imagen , Cardiopatías/epidemiología , Tabiques Cardíacos/diagnóstico por imagen , Humanos , MasculinoRESUMEN
AIM: To compare the effects of renal transplantation on cardiac functions in children and adults. METHODS: One hundred and ten patients attending the nephrology outpatient clinic were enrolled in this study and were divided into six groups. The first two groups consisted each of 30 renal transplant patients who had a successful renal transplantation more than six months, but less than one year. Group I were less than 18 years and group II were more than 18 years. The third and fourth groups, each were 20 chronic renal failure patients on regular hemodialysis. Again, group III were less than 18 years and group IV were more than 18 years. Group V and VI (The control Groups) consisted each of 5 subjects below and above 18 years of age, respectively with normal kidney functions. All patients were subjected to history and examination. The kidney functions and the hemoglobin were analyzed. After obtaining informed consent, echocardiography was done to all patients. RESULTS: There was a statistically significant improvement (P < 0.0001) in all cardiac parameters. A regression in left ventricular end diastolic volume (LVED) both in children (4.7 ± 0.8 to 4.2 ± 0.5) and in adults (5.9 ± 0.7 to 4.9 ± 0.6) were found. There was a regression in left ventricular end systolic volume (LVES) both in children (3.1 ± 0.6 to 2.4 ± 0.4) and in adults (4.1 ± 0.9 to 3.1 ± 0.5). Fractional shortening improves both in children (32.6 ± 5.3 to 41.7 ± 7.6) and in adults (29.0 ± 6.6 to 36.5 ± 4.1). The improvement in ejection fraction (EF) was higher in children (59.7 ± 7.0 to 71.9 ± 6.1) than in adults (52.0 ± 12.5 to 64.8 ± 5.9). However, this degree of improvement (in children: 12.2 ± 5.1) did not show statistical difference (P-value 0.8), when compared to adults (12.7 ± 9.8). CONCLUSION: After renal transplantation cardiac functions and morphology (EF/LVED/LVES) do improve markedly and rapidly in both children and adults.
RESUMEN
BACKGROUND: Persistent hyperparathyroidism (HPT) with hypercalcemia is prevalent after transplant and is considered a risk factor for progressive bone loss and fractures and vascular calcification, as well as the development of tubulointerstitial calcifications of renal allografts and graft dysfunction. The subtotal parathyroidectomy is the standard treatment, although currently it has been replaced by the calcimimetic cinacalcet. AIM: The hypothesis of this study is that subtotal parathyroidectomy is superior to cinacalcet for treatment of persistent secondary parathyroidectomy post renal transplant, with minimal morbidity and significantly it reduces the cost of treatment after transplantation. METHODS: We report our long-term clinical experience with either cinacalcet or parathyroidectomy in 59 kidney transplant recipients with hyperparathyroidism. Group one included medical treatment with cinacalcet and had 45 patients while parathyroidectomy patients (group 2) were 16 patients with two of them excluded because of surgical failure. RESULTS: No difference was found between groups for any parameter. A greater short-term change of calcium and phosphorus homeostasis obtained by surgery than by cinacalcet, and in long term change, no significant difference between the two groups. CONCLUSIONS: The main findings of this study are that correction of severe hyperparathyroidism was similar in both surgical and cinacalcet groups with the absence of a difference of long-term serum iPTH 1-84 levels between the two groups.
Asunto(s)
Calcimiméticos/uso terapéutico , Cinacalcet/uso terapéutico , Hiperparatiroidismo Secundario/tratamiento farmacológico , Hiperparatiroidismo Secundario/cirugía , Trasplante de Riñón/efectos adversos , Paratiroidectomía , Adolescente , Adulto , Femenino , Humanos , Hiperparatiroidismo Secundario/etiología , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/terapia , Adulto JovenRESUMEN
OBJECTIVES: The aim of this study was to evaluate the effectiveness of sitagliptin, alone or in combination with metformin, in kidney transplant patients with newly diagnosed new-onset diabetes mellitus after transplant who had inadequate glycemic control, compared with a group of patients receiving insulin glargine with special emphasis on weight gain. MATERIALS AND METHODS: Newly diagnosed renal transplant patients with new-onset diabetes mellitus after a transplant was defined by a blood glucose ≥ 11.1 mmol/L after an oral glucose tolerance test were examined. They were treated with standard immunosuppression composed of triple therapy with tacrolimus or cyclosporine, mycophenolate mofetil or azathioprine, and prednisone. They had stable graft function for more than 6 months after the transplant. RESULTS: Patients with new-onset diabetes mellitus after transplant (n=28) whose glycemia was not controlled adequately with oral hypoglycemic agents (either alone or in combination) received oral sitagliptin 100 mg once daily in addition to existing therapy for 12 weeks. Patients who received insulin glargine as add-on therapy (n=17) served as the control group. Data analyses included glycated hemoglobin, fasting plasma glucose, lipid profile, body weight, and the occurrence of hypoglycemia. We found significant reductions in glycated hemoglobin and fasting plasma glucose values after 12 weeks of additional sitagliptin therapy that were comparable to those with insulin glargine. While the addition of stagliptin resulted in a small weight loss (0.4 kg), the addition of insulin glargine resulted in a weight gain (0.8 kg). The overall incidence of adverse experiences was low and generally mild in both groups. CONCLUSIONS: In a group of renal transplant recipients with new-onset diabetes mellitus after a transplant in whom glycemia was not controlled adequately by oral hypoglycemic agents, the addition of sitagliptin helped to achieve glycemic control similar to insulin glargine but with a marginal weight advantage.